Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Valeant And Watson Buy Into Generics
by Ann M. Thayer
May 30, 2011
| A version of this story appeared in
Volume 89, Issue 22
Looking to spend its money after failing to take over Cephalon, Valeant Pharmaceuticals will acquire the specialty drug firm AB Sanitas for about $443 million in cash. Based in Kaunas, Lithuania, Sanitas sells branded generic drugs throughout Central and Eastern Europe. Valeant expects its sales to reach more than $140 million this year. Separately, Watson Pharmaceuticals has bought the generic drug maker Specifar Pharmaceuticals for $562 million. The Greek firm had 2010 sales of about $120 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X